ATRYS HEALTH, S.A. | Sales 2024 * | 220M 239M 18.92B | Sales 2025 * | 236M 257M 20.3B | Capitalization | 275M 298M 23.6B |
|---|---|---|---|---|---|
| Net income 2024 * | -2M -2.17M -172M | Net income 2025 * | 4M 4.34M 343M | EV / Sales 2024 * | 2.03 x |
| Net Debt 2024 * | 173M 188M 14.87B | Net Debt 2025 * | 160M 174M 13.78B | EV / Sales 2025 * | 1.84 x |
| P/E ratio 2024 * |
-110
x | P/E ratio 2025 * |
65.8
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 48.57% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 12/06/07 | |
| Director of Finance/CFO | - | 31/07/15 | |
| Corporate Secretary | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 48 | 31/01/16 | |
| Director/Board Member | - | - | |
Aurora Catá Sala
BRD | Director/Board Member | 60 | - |
Atrys Health SA, formerly Europath Biosciences SL, is Spain-based company primarily engaged in the predictive and personalized oncology therapies. It operates under Atrys brand name. Atrys is a clinical and translational research laboratory dedicated to the diagnosis, prognosis and treatment of cancer, including hematologic and solid malignancies. It has four areas of activity: Laboratory, Telemedicine, Radiotherapy, as well as Research and Development (R&D). The Company has its diagnostic laboratories and translational research in Barcelona and Granada, and offices in Madrid, Spain.
| 1st Jan change | Capi. | |
|---|---|---|
| +20.75% | 85.64B | |
| -27.51% | 70.63B | |
| +4.65% | 27.05B | |
| -5.72% | 17.97B | |
| +1.71% | 17.58B | |
| +2.64% | 15.64B | |
| +9.46% | 13.55B | |
| +9.48% | 13.41B | |
| +70.19% | 13.18B |
